Last reviewed · How we verify
Immunoscintigraphy with radiolabeled Cimzia®.
Radiolabeled Cimzia (certolizumab pegol) is used as an imaging agent to visualize and localize TNF-α-expressing immune cells in inflammatory disease sites.
Radiolabeled Cimzia (certolizumab pegol) is used as an imaging agent to visualize and localize TNF-α-expressing immune cells in inflammatory disease sites. Used for Imaging of TNF-α-expressing immune cells in inflammatory diseases (Phase 3 investigational).
At a glance
| Generic name | Immunoscintigraphy with radiolabeled Cimzia®. |
|---|---|
| Sponsor | University Hospital, Ghent |
| Drug class | Radiolabeled TNF-α inhibitor monoclonal antibody |
| Target | TNF-α |
| Modality | Small molecule |
| Therapeutic area | Immunology / Diagnostic Imaging |
| Phase | Phase 3 |
Mechanism of action
Cimzia is a TNF-α inhibitor monoclonal antibody that, when radiolabeled, allows scintigraphic imaging of TNF-α-producing cells at sites of inflammation. This diagnostic approach enables non-invasive visualization of disease activity and localization in inflammatory conditions. The radiolabel allows detection via nuclear imaging while the antibody provides specific targeting to TNF-α-expressing immune cells.
Approved indications
- Imaging of TNF-α-expressing immune cells in inflammatory diseases (Phase 3 investigational)
Common side effects
- Radiation exposure (minimal from diagnostic dose)
- Infusion-related reactions
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: